Navigation Links
Dr. Michael Hanley Joins Celtaxsys as CEO
Date:12/2/2010

ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors.  Dr. Hanley has served on both the Scientific Advisory Board and Board of Directors of Celtaxsys since 2007. Dr. Hanley brings more than 20 years of managerial experience in the international life science industry including drug discovery, product development, and production.  He was most recently the Chief Scientific Officer for Amylin Pharmaceuticals where he was responsible for discovery research and preclinical development.  

"We are very pleased that Dr. Hanley has joined us as CEO," says William Reddick, CFO and Founder of Celtaxsys. "His background as an industry leader, and as an innovative drug hunter, with direct knowledge of our area of research, are qualities well-matched to our needs. We are delighted in the strengths he brings to Celtaxsys."  

"Over the last few years I have gained an insight into the innovative technology and exciting research and development that are at the core of Celtaxsys. I look forward towards building long-term, future success and stakeholder value at the Company," says Michael Hanley.  

From 1981 to 1997, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. From 1997 to 2003, he was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr. Hanley has founded several start-ups, such as Resolvyx Pharmaceuticals and Psylin Neurosciences, and is currently on boards of Aileron Therapeutics, Metabolic Solutions Development Company, Isogenica, and Pieris.
'/>"/>

SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
2. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
3. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
4. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
5. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
6. Michael Garippa Joins SynCardia as President
7. 2010 Michael E. DeBakey Journalism Awards Announced
8. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
9. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
10. Michael Sitaras of SavATree Earns ISA Certified Arborist Designation
11. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today announced a ... archwire that allows orthodontists to simultaneously apply different forces to different teeth. The ... “We’re thrilled about taking SmartArch one step closer to commercial availability for orthodontists ...
(Date:6/29/2015)... ... 30, 2015 , ... This cutting edge standard making is a madatory tool ... peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets metrologists and ... range. Previous spectrophotometer calibration standards, such as those made from didymium glass were only ...
(Date:6/29/2015)... ... June 29, 2015 , ... MediVet Biologics ... of the agreement, MediVet will acquire the rights to a portfolio of cultures, ... in pre-clinical development as a potential next-generation treatment for various musculoskeletal and internal ...
(Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... limped off the pitch, thereby ending his chances of ... injuries and rehabilitation techniques were once again front and ... to one player,s Achilles tendon is a sign of ... of research. Now Paul Comfort and Earle Abramson,s pioneering ...
... genome, a new resource has been made available to ... BioMed Central, the open access publisher, touches upon several ... series, a study published in BMC Neuroscience ... and estrogen biosynthesis. Researchers writing in BMC Genomics ...
... yourself leading groups, or are you naturally more comfortable following ... be a leader you,re better off at the edges of ... In a series of experiments on crowd behaviour, a ... University of Leeds also found that successful leaders display more ...
Cached Biology News:Sports rehabilitation and injury prevention 2Follow the leader: How those in charge make themselves known 2
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: